HENDERSON MOLLY (CFO and CBO) received a stock award from PHATHOM PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 3/3/2025ACC: 0000950170-25-031042
Officer· CFO and CBO
Since Apr 2022
+122K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
122K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+72K
Price / share
—
Trade value
—
% of position
77.0%
2/27/2025
93.55K→165.55K
Total
Net shares
+72K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/27/2025 | A · Award | +72K | — | — | 77.0% | 93.55K | 165.55K |
| Total | +72K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
50K shares
Shares
+50K
Strike price
5.76
Held after
50K
Exercisable
—
2/27/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock50K shares | 2/27/2025 | A · Award | +50K | 5.76 | — | 50K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned1.91K
Total
1.91K indirect1.91K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.91K | Indirect |
| Total | 1.91K | 1.91K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported